But the most powerful way to use genomic testing is to proactively support each person’s unique biochemistry through Genomic Medicine – using personalized diet, lifestyle and medication strategies within a. This link to their “Oncotype DX” page (here) outlines the this genomic test in more detail. Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. Genomics focuses on the interaction of genes and small changes called “SNPs” that can affect how they function within your body and how they interact with your environment to affect the manifestation of diseases. Oncotype DX results are now incorporated into NCCN Breast Cancer Clinical Practice Guidelines, ASCO guidelines, and the 8th Edition of the AJCC Breast Cancer Staging Manual. This test also accounts for tumor size in helping determine if chemotherapy may be needed in early stage, favorable breast cancers. Information about genomic mutations that are unique to your individual cancer … The purpose of this test is to better identify people who do and do not benefit from chemotherapy. This non-profit organization provides excellent patient resources about breast cancer. Read more about health conditions that can be addressed with Genomic Medicine. If you want to get deep into the details, this free 200-page pdf document (here) has guidelines to help clinicians to make treatment recommendations about nearly all aspects of breast cancer. Modern medicine is embracing genomics as a way to understand how genes and the environment interact to cause disease. This page (here) “What is Endopredict?” provides an overview about this breast cancer genomic test. Genomic testing is being used in all sorts of medical fields. View our video lesson on “BRCA Genetic Testing” (here) to learn more about genetic testing for breast cancer. This simple “Genetics vs Genomics” brochure (here) simply outlines the differences between these two very important terms. It can help determine if someone will benefit (or can avoid) five additional years of hormonal therapy, such as tamoxifen or an aromatase inhibitor. Researchers mapped the entire human genetic code, discovering that every human cell is packed with an estimated 20,000 to 30,000 genes. NCCN Breast Cancer Clinical Practice Guidelines. Your medical oncologist will examine multiple factors to help determine if you will benefit from chemotherapy. Be your own advocate. Breast Cancer School for Patients. Patients who have small “Estrogen receptor positive” (ER+) and “HER2 receptor negative” (HER2-) tumors and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX assay. Although their names are similar, and they are related, genetics and genomics are not the same thing. (You can unsubscribe anytime). The Susan G. Komen organization is a leading advocacy group dedicated to assisting patients, funding research, and ensuring quality breast cancer care. Unfortunately, these sophisticated tests are not embraced by some breast cancer specialists. Unlike genetic testing that looks at specific genes and the impact of mutations on specific diseases, genomics studies large sections of data. This assay of DCIS or “precancerous” breast cells may help identify some women who may not benefit from radiation therapy after a lumpectomy. Read more about health conditions that can be addressed with Genomic Medicine, Learn more about using Genomic Medicine in your practice, Using a Polygenic Genomics Approach to Modify Genetic Disease Risk. This website (here) provides more information about the Oncotype DX assay from it’s manufacturer, Genomic Health Inc. Genomic Health Inc. is a leading personalized medicine company. It takes about two weeks to get the results. This test is designed for women with favorable, early stage breast cancer who have been on hormonal therapy for 4 to 5 years. Read more about the difference between genetics and genomics. This test is now included in national guidelines for some with hormone sensitive breast cancers that are found to have a small amount of cancer in a few lymph nodes. Teaching everyone to be an expert in their own breast cancer care. A breast tumor, for example, may look and act like a lung tumor. The analyses may help doctors consider more precise therapies in many cases, but not all mutations can be matched with known treatment options. Therefore, if you make your first medical oncology consultation appointment about three weeks after the test is ordered, you will have all the information needed to make a definitive decision about chemotherapy and hormonal therapy. EndoPredict is a 2nd generation genomic breast cancer recurrence test to assess for 10-year risk of cancer recurrence. Cancer treatment has typically followed a similarly generalized line of attack. Myriad Genetics is global leader in genetic testing and personalized medicine. Most genomic tests are covered by Medicare and commercial insurance companies. Genomic testing is being used in all sorts of medical fields. If you or your caregivers have additional questions, we will offer resources and educational guidance on this emerging field of medicine. If there’s a match, your oncologist may be able to use the results to suggest treatments that have been used in the past to target the same mutations. This test is not yet approved by the FDA. (video disclaimer), Contact Us: contact@breastcancercourse.org, Press Inquiries: pr@breastcancercourse.org. DNA-directed dietary, lifestyle, supplement and even medication interventions, are changing our ability to maximize health and wellness. Genomic Health Inc. is a leading personalized medicine company.